STL Volume 12 Number 6

Update on Drugs and Drug News

Update on Drugs and Drug News – July-August 2007

Update on Hyaluronic Acid Gel Particles PERLANE®, Cervical Cancer Vaccine Cervarix®, Vaccinia Immune Globulin Intravenous (Human), Levocetirizine Dihydrochloride Xyzal®, and Infliximab Remicade®.
image of silk fabric and dry skin

Rituximab: A B-Cell Depletion Therapy for Dermatologic Disease

Rituximab (Rituxan®, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20. While anecdotal case reports recommend its “off-label” use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy.
image of silk fabric and dry skin

Cutaneous Reactions to Anticancer Agents Targeting the Epidermal Growth Factor Receptor: A Dermatology-Oncology Perspective

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.